Agenus (AGEN) Rating Lowered to Buy at BidaskClub

Agenus (NASDAQ:AGEN) was downgraded by analysts at BidaskClub from a “strong-buy” rating to a “buy” rating in a research note issued to investors on Monday.

Several other equities analysts have also recently weighed in on AGEN. ValuEngine raised shares of Agenus from a “sell” rating to a “hold” rating in a research report on Wednesday, May 2nd. Zacks Investment Research cut shares of Agenus from a “hold” rating to a “sell” rating in a research report on Tuesday, March 20th.

Get Agenus alerts:

NASDAQ AGEN remained flat at $$2.70 during trading hours on Monday. 1,277,934 shares of the company traded hands, compared to its average volume of 1,578,324. Agenus has a twelve month low of $2.70 and a twelve month high of $6.19. The company has a market cap of $280.80 million, a PE ratio of -2.20 and a beta of 1.70. The company has a debt-to-equity ratio of -0.11, a quick ratio of 2.16 and a current ratio of 2.16.

Agenus (NASDAQ:AGEN) last announced its quarterly earnings results on Monday, May 7th. The biotechnology company reported ($0.42) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.28) by ($0.14). equities analysts predict that Agenus will post -1.57 EPS for the current fiscal year.

A number of hedge funds and other institutional investors have recently made changes to their positions in AGEN. Point72 Asset Management L.P. bought a new position in Agenus in the 1st quarter valued at about $16,342,000. Artal Group S.A. lifted its position in Agenus by 10.0% in the 1st quarter. Artal Group S.A. now owns 2,750,000 shares of the biotechnology company’s stock valued at $12,953,000 after acquiring an additional 249,745 shares in the last quarter. Hudson Bay Capital Management LP lifted its position in Agenus by 60.7% in the 4th quarter. Hudson Bay Capital Management LP now owns 450,000 shares of the biotechnology company’s stock valued at $1,467,000 after acquiring an additional 170,000 shares in the last quarter. UBS Group AG lifted its position in Agenus by 1,180.3% in the 1st quarter. UBS Group AG now owns 137,417 shares of the biotechnology company’s stock valued at $647,000 after acquiring an additional 126,684 shares in the last quarter. Finally, RTW Investments LP lifted its position in Agenus by 2.6% in the 4th quarter. RTW Investments LP now owns 4,329,816 shares of the biotechnology company’s stock valued at $14,115,000 after acquiring an additional 111,296 shares in the last quarter. 45.60% of the stock is currently owned by institutional investors and hedge funds.

Agenus Company Profile

Agenus Inc, a clinical-stage immuno-oncology company, focuses on the discovery and development of therapies that engage the body's immune system to fight cancer. The company offers Retrocyte Display, an antibody discovery platform for the identification of fully-human and humanized monoclonal antibodies; SECANT yeast display, an antibody discovery platform used for the generation of novel monoclonal antibodies; and phage display technologies.

Leave a Reply

Your email address will not be published. Required fields are marked *